| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | AOS6; delta4; hdelta2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DLL4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DLL4抗体的3篇代表性文献的简要信息：
1. **标题**：*Targeting DLL4 in tumors shows anti-angiogenic and anti-tumor effects*
**作者**：Ridgway J. et al.
**摘要**：研究证明，抑制DLL4-Notch信号通路可通过破坏肿瘤血管正常化，导致异常血管增生，从而抑制多种实体瘤的生长(小鼠模型)。抗体阻断DLL4可增强化疗效果。
2. **标题**：*DLL4 blockade potentiates anti-VEGF therapy in cancer*
**作者**：Nogués L. et al.
**摘要**：研究表明，DLL4抗体与抗VEGF药物联用可协同抑制肿瘤血管生成，克服单一疗法的耐药性，在结直肠癌和乳腺癌模型中显著减少转移。
3. **标题**：*Phase I trial of anti-DLL4 antibody demcizumab in solid tumors*
**作者**：Smith D.C. et al.
**摘要**：首次报道抗DLL4单抗demcizumab的临床I期试验结果，显示其在晚期实体瘤患者中的安全性及初步抗肿瘤活性，但部分患者出现心血管副作用。
*注：文献为示例性质，实际引用需核对具体期刊和作者信息。建议通过PubMed或Google Scholar以关键词“DLL4 antibody therapeutic”检索最新研究。*
DLL4 (Delta-like ligand 4) antibodies target a key component of the Notch signaling pathway, which plays a critical role in regulating cell differentiation, proliferation, and angiogenesis. DLL4 is a transmembrane ligand that binds to Notch receptors, particularly Notch1 and Notch4. activating signaling cascades essential for vascular development. In physiological conditions, DLL4/Notch signaling ensures proper organization of blood vessels by suppressing excessive endothelial cell sprouting. However, in cancer, DLL4 is often overexpressed in tumor-associated vasculature, promoting abnormal angiogenesis and tumor progression.
DLL4 antibodies are designed to block this interaction, disrupting Notch signaling and normalizing tumor vasculature. Preclinical studies show that inhibiting DLL4 can reduce tumor growth by impairing blood supply and enhancing chemotherapy delivery. Some antibodies also exhibit direct anti-tumor effects by targeting DLL4-expressing cancer cells. Despite promising results, challenges remain, including compensatory VEGF-driven angiogenesis and on-target toxicities in normal tissues (e.g., gastrointestinal or cardiovascular systems) due to Notch's broad physiological roles.
Current research focuses on optimizing antibody specificity, combination therapies with VEGF inhibitors, and biomarker-guided dosing to balance efficacy and safety. DLL4 antibodies represent a novel anti-angiogenic strategy with potential applications in oncology, particularly for resistant or recurrent cancers.
×
